Understanding the immunological landscape of England during SARS-CoV2 Omicron variant waveArticle Published on 2022-10-142022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] B.1.1.529 booster dose Cell country defined dose Endemic England estimate Evidence expected groups immune evasion Immunity immunological increased risk indicated Infection iterative less National Older age omicron Population proportion public health SARS-CoV2 Spread understanding Vaccine variant variants virus [DOI] 10.1371/journal.pone.0264870 PMC 바로가기
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyArticle Published on 2022-10-142022-11-15 Journal: eLife [Category] COVID19(2023년), SARS, 바이오마커, 진단, [키워드] Abuse Accelerator Antibody Response association Biomarker BNT162b2 characterized clinical trial coronavirus Course COVID-19 COVID-19 patients Critical CXCL10 cytokine dataset develop Disease progression Donor drug early IFN signaling Eiger BioPharmaceuticals enrolled Enrollment heterogeneity Host identify immune immune marker immune response immune signature immunological immunology independent individual Infection Infectious disease Inflammation machine-learning majority marker MCP-3 MCP1 Medicine memory Mild mRNA vaccination natural infection outcome Outpatient outpatients Patient Pfizer-BioNTech plasma plasma protein Post-infection predict Predictive Predictive modeling proteomics provided receiving RIG-I SARS-CoV-2 SARS-CoV-2-infected patients severe symptoms Stanford Stanford University subsequent systems immunology T cell T cell memory the antibody response trajectory transcriptomics Vaccine viral shedding Virological viruses with COVID-19 [DOI] 10.7554/eLife.77943 PMC 바로가기
Adaptive immunity to SARS-CoV-2 infection: A systematic reviewArticle Published on 2022-10-102022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute respiratory syndrome adaptive Adaptive immunity addressed Alpha Antigen article B cell Biomarker case-control study caused CD4+ T cell CD8+ CD8+ T lymphocytes Cell cell types Characteristics clinical benefits Cohort studies coronavirus coronavirus disease Course COVID-19 Critically ill Critically ill patient cross-sectional CXCL9 Cytokines database disease English Evidence experimental evidence follicular HLA-DR humoral Humoral immunity IL-10 IL-13 IL-15 IL-17 IL-1α IL-2 IL-21 IL-22 IL-23 IL-4 IL-5 IL-7 immune system Immunity immunological Immunological memory immunopathological in vitro assays individuals inflammatory mediator involved leukocyte Ligand lymphocyte marker mild case Necrosis poor prognosis predominant produced programmed cell death progression Protein Regulatory T cell responsible SARS-CoV-2 SARS-COV-2 infection SciELO secretion severity Spanish subpopulation systematic review T helper T helper cell T lymphocyte T-cell Response Tfh TGF-β Th1 Th17 Th2 the antibody the disease TNF-α Treg tumor growth Vaccine variable [DOI] 10.3389/fimmu.2022.1001198 PMC 바로가기
Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, IndiaArticle Published on 2022-10-062022-11-15 Journal: Frontiers in Public Health [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI affecting age all age groups Antenatal anti-Nucleocapsid IgG Anti-spike anti-spike antibody antibodies antibody assigned attribute blood sample Cluster collected Community Comorbidity conducted Coverage COVID-19 cross-sectional cross-sectional survey cumulative death Epidemiology fatality female gender General population healthcare healthcare personnel household IgG IgG antibodies IgM IgM antibodies immunological India indicate Infection Kashmir less Logistic regression Logistic regression analysis occurred Odds ratio pandemic participant positive processed questionnaire reported SARS-CoV-2 second wave selected Sensitivity and specificity seropositive Seroprevalence significantly Testing the SARS-CoV-2 transferred vaccination variable venous was collected was done women [DOI] 10.3389/fpubh.2022.967447 PMC 바로가기
Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccinesArticle Published on 2022-10-042022-11-15 Journal: PLoS Pathogens [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Activation antibody Antibody Response Antibody titre antigen exposure baseline benefit binding BNT162b2 boost CD4+ T cell CD8+ Cellular immune response clinical trial Course COVID-19 Delta dose ELISA ELISPOT enhanced global public health glycoprotein Heterologous highest humoral immune memory immune response immunological increase in individual majority marker median mRNA mRNA COVID-19 vaccine mRNA vaccination mRNA vaccine naïve natural infection neutralising antibody titre omicron participant Participants PCR proportion question receiving recruited response RNA SARS-CoV-2 vaccine second dose seroconverted significantly higher subject the SARS-CoV-2 titre vaccination Vaccination strategy Vaccine variants were measured wildtype [DOI] 10.1371/journal.ppat.1010885 PMC 바로가기
MIS-C: A COVID-19-as sociated condition between hypoimmunity and hyperimmunityArticle Published on 2022-10-032022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 바이오마커, 변종, [키워드] activated Activation acute phase Admission Analysis ATM Autoimmune Autoimmune disease Autoimmune diseases autoimmune pathogenesis autoinflammatory disease Autoinflammatory diseases B cell cellular Characteristics children clearance complication of COVID-19 contribute Critical cytokine response Cytokine storm Cytokines Cytometry demonstrated develop diagnostic biomarker DOCK8 event FCN3 Flow flow cytometry Genetic Genetic variant healthy control help heterogeneity Hospital admission identified variant IFN IFN-α IFN-β IFN-γ IFNγ IL-10 IL-12p70 IL-17A IL-6 immune dysregulation immunodeficiency immunological induce Inflammatory inflammatory pathway involved knowledge lymphocyte lymphopenia management MCM4 MIS-C MOST multisystemic mutated NCF1 NGS NOD2 organ Pathogenesis pathway Patient patients Population PRF1 reduction serum serum cytokine significant increase syndrome Th1 the disease therapeutic Therapies tissue damage TNF Type variant was increased [DOI] 10.3389/fimmu.2022.985433 PMC 바로가기
SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificityArticle Published on 2022-10-032022-11-15 Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] airway analyzed antiviral immunity Breakthrough infection CD4+ T cell CD8+ COVID-19 COVID-19 vaccinee feature highlight Immunity immunological induce Infection nasal nasal mucosa persistence phenotype Primary infection Rapid SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins SARS-CoV-2 vaccination SARS-CoV-2-infected cell specificity suppress T cell T cell response vaccination vaccinee [DOI] 10.1084/jem.20220780 PMC 바로가기
Calibration and Validation of a Mechanistic COVID-19 Model for Translational Quantitative Systems Pharmacology – A Proof-of-Concept Model Development for RemdesivirArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] COVID19(2023년), SARS, 치료제, [키워드] accelerate Administered antibody approach calibrated calibration clinical Clinical data Clinical outcome clinical setting clinical study Clinical trial design coronavirus disease Course COVID-19 COVID-19 disease COVID-19 therapeutics Cytokines development disease drug candidate example global pandemic immune responses immunological in silico include intravenously lymphopenia metabolism metabolite Mild Model Patient pharmacological Pharmacology Placebo predict provide quantitative framework Remdesivir responses severe COVID-19 System the disease the primary endpoint Therapies therapy Time to recovery translate validation viral titer virus infection [DOI] 10.1002/cpt.2686 PMC 바로가기
Single-cell transcriptome analyses reveal distinct gene expression signatures of severe COVID-19 in the presence of clonal hematopoiesisArticle Published on 2022-10-012022-11-16 Journal: Experimental & Molecular Medicine [Category] 변종, 유전자 메커니즘, [키워드] Analysis ChIP chromatin chromatin architecture classical monocytes clinical impact COVID-19 dissect element exacerbating exhibited facilitate Gene Expression gene expression signature Hematopoiesis highlight hyperinflammation IFN-γ immunological individual Inflammation inflammatory immune response Inflammatory responses interactions mechanism methylated mononuclear cells Patient Peripheral blood putative target gene Region Regulatory reported severe COVID-19 severe COVID-19 patients severity single-cell susceptibility Transcriptome with COVID-19 [DOI] 10.1038/s12276-022-00866-1 PMC 바로가기
The next frontier in vaccine design: blending immune correlates of protection into rational vaccine designReview Published on 2022-10-012022-10-05 Journal: Current opinion in immunology [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, [키워드] accelerate accelerated antibody Antibody binding canonical Community Complete death embedding immune correlate Immune profile Immunity immunological lack neutralization pathogen populations protective vaccines question raised severe disease the vaccine to define Vaccine Vaccine design Vaccine development Vaccines variants of concern Viral variants waned [DOI] 10.1016/j.coi.2022.102234 [Article Type] Review